Strongyloides stercoralis in chronic renal failure: safe therapy with thiabendazole.
The pharmacodynamics of thiabendazole (TBZ) and its metabolite, 5OH-thiabendazole (5OH-TBZ), were studied in an anephric patient with Strongyloides stercoralis pneumonitis. No toxic manifestations were noted in the patient, and serum TBZ and 5OH-TBZ levels were comparable to those in eunephric patients. We conclude that thiabendazole, in the usual recommended dose of 25 mg/kg twice daily, given to patients with compromised renal function is reasonable and safe.
D000328:Adult; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy; D007676:Kidney Failure, Chronic / Q000150:complications*; D016030:Kidney Transplantation; D008174:Lung Diseases, Parasitic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D013322:Strongyloidiasis / Q000150:complications / Q000188:drug therapy*; D013827:Thiabendazole / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D013827:Thiabendazole